From pathogenesis to personalized treatments of neuropathies in hematological malignancies.
ibrutinib
lymphoma
monoclonal gammopathy
neurolymphomatosis
neuropathy
obinutuzumab
rituximab
Journal
Journal of the peripheral nervous system : JPNS
ISSN: 1529-8027
Titre abrégé: J Peripher Nerv Syst
Pays: United States
ID NLM: 9704532
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
08
06
2020
revised:
13
07
2020
accepted:
14
07
2020
pubmed:
21
7
2020
medline:
28
9
2021
entrez:
21
7
2020
Statut:
ppublish
Résumé
The peripheral nervous system may be involved at any stage in the course of several hematological diseases, the most common being monoclonal gammopathies (of undetermined significance or malignant) or lymphomas. The underlying pathogenic mechanisms are different and therapies aim at targeting the dangerous either B-cell or plasma cell clones. Recently, high-throughput technologies, and next-generation sequencing have increased our knowledge of hematological diseases pathogenesis by the identification of somatic mutation affecting pivotal signaling pathways. Accordingly, new target therapies are used that may also be borrowed for treatment of neuropathies in hematological diseases.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
212-221Informations de copyright
© 2020 Peripheral Nerve Society.
Références
Briani C, Visentin A, Campagnolo M, et al. Peripheral nervous system involvement in lymphomas. J Peripher Nerv Syst. 2019;24:5-18.
Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature. 2010;465:885-890.
Piazza F, Manni S, Arjomand A, Visentin A, Trentin L, Semenzato G. New responsibilities for aged kinases in B-lymphomas. Hematol Oncol. 2020;38:3-11.
Severin F, Frezzato F, Visentin A, et al. In chronic lymphocytic leukemia the JAK2/STAT3 pathway is constitutively activated and its inhibition leads to CLL cell death unaffected by the protective bone marrow microenvironment. Cancers (Basel). 2019;11(2):1939.
Frezzato F, Raggi F, Martini V, et al. HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia. Int J Cancer. 2019;145:3089-3100.
Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115-119.
de Groen RAL, Schrader AMR, Kersten MJ, Pals ST, Vermaat JSP. MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications. Haematologica. 2019;104:2337-2348.
Yu X, Li W, Deng Q, et al. MYD88 L265P mutation in lymphoid malignancies. Cancer Res. 2018;78:2457-2462.
Dubois S, Viailly PJ, Bohers E, et al. Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-cell lymphoma: analysis of 361 cases. Clin Cancer Res. 2017;23:2232-2244.
Martini V, Gattazzo C, Frezzato F, et al. Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. Br J Haematol. 2017;178:81-93.
Treon SP, Xu L, Liu X, Hunter ZR, Yang G, Castillo JJ. Genomic landscape of Waldenstrom Macroglobulinemia. Hematol Oncol Clin North Am. 2018;32:745-752.
Nakamura A, Ohwada C, Takeuchi M, et al. Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenstrom's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. PLoS One. 2019;14:e0221941.
Bagratuni T, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. Leukemia. 2018;32:2617-2625.
Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal Gammopathy of undetermined significance. N Engl J Med. 2018;378:241-249.
Campagnolo M, Ferrari S, Dalla Torre C, et al. Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment. J Neuroimmunol. 2015;281:1-4.
Boso F, Ruggero S, Giannotta C, et al. Anti-sulfatide/galactocerebroside antibodies in immunoglobulin M paraproteinemic neuropathies. Eur J Neurol. 2017;24:1334-1340.
Rajabally YA. Neuropathy and paraproteins: review of a complex association. Eur J Neurol. 2011;18:1291-1298.
Willison HJ, O'Leary CP, Veitch J, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain. 2001;124:1968-1977.
Latov N. Diagnosis and treatment of chronic acquired demyelinating polyneuropathies. Nat Rev Neurol. 2014;10:435-446.
Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2016;10:CD002827.
Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65:286-293.
Leger JM, Viala K, Nicolas G, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80:2217-2225.
Dalakas MC. Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Ther Adv Neurol Disord. 2018;11:1756285617746640.
Campagnolo M, Zambello R, Nobile-Orazio E, et al. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. J Neurol Neurosurg Psychiatry. 2017;88:1094-1097.
Hospital MA, Viala K, Dragomir S, et al. Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients. Haematologica. 2013;98:e155-e157.
Gruson B, Ghomari K, Beaumont M, et al. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. J Peripher Nerv Syst. 2011;16:180-185.
Massa F, Zuppa A, Pesce G, et al. Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. J Neurol Sci. 2020;413:116777.
Castellani F, Visentin A, Campagnolo M, et al. The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. Neurol Neuroimmunol Neuroinflamm. 2020;7:e720.
Briani C, Visentin A, Salvalaggio A, et al. Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. Haematologica. 2017;102:e140-e143.
Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353-1363.
Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4:38.
Obici L, Adams D. Acquired and inherited amyloidosis: knowledge driving patients' care. J Peripher Nerv Syst. 2020;25:85-101.
Manni S, Brancalion A, Mandato E, et al. Protein kinase CK2 inhibition down modulates the NF-kappaB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. PLoS One. 2013;8:e75280.
Dispenzieri A. POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol. 2019;94:812-827.
Dacci P, Lessi F, Dalla Bella E, Morbin M, Briani C, Lauria G. Ischemic stroke as clinical onset of POEMS syndrome. J Neurol. 2013;260:3178-3181.
Cerri F, Falzone YM, Riva N, Quattrini A. An update on the diagnosis and management of the polyneuropathy of POEMS syndrome. J Neurol. 2019;266:258-267.
Briani C, Fabrizi GM, Ruggero S, et al. Vascular endothelial growth factor helps differentiate neuropathies in rare plasma cell dyscrasias. Muscle Nerve. 2011;43:164-167.
Briani C, Dalla Torre C, Lessi F, et al. Pentraxin-3 and VEGF in POEMS syndrome: a 2-year longitudinal study. J Neuroimmunol. 2014;277:189-192.
Scarlato M, Previtali SC, Carpo M, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain. 2005;128:1911-1920.
Nagao Y, Mimura N, Takeda J, et al. Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia. 2019;33:1723-1735.
Furukawa Y, Kikuchi J. Molecular basis of clonal evolution in multiple myeloma. Int J Hematol. 2020;111:496-511.
Adams D, Said G. Ultrastructural characterisation of the M protein in nerve biopsy of patients with POEMS syndrome. J Neurol Neurosurg Psychiatry. 1998;64:809-812.
Piccione EA, Engelstad J, Dyck PJ, Mauermann ML, Dispenzieri A, Dyck PJ. Nerve pathologic features differentiate POEMS syndrome from CIDP. Acta Neuropathol Commun. 2016;4:116.
Briani C, Fedrigo M, Manara R, et al. Pachymeningeal involvement in POEMS syndrome: MRI and histopathological study. J Neurol Neurosurg Psychiatry. 2012;83:33-37.
Ziff OJ, Hoskote C, Keddie S, D'Sa S, Davangnanam I, Lunn MPT. Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome. J Neurol. 2019;266:1067-1072.
Guibert C, Richard L, Durand S, et al. Skin and Nerve neovascularization in POEMS syndrome: insights from a small cohort. J Neuropathol Exp Neurol. 2020;79:542-550.
Kourelis TV, Buadi FK, Kumar SK, et al. Long-term outcome of patients with POEMS syndrome: an update of the Mayo Clinic experience. Am J Hematol. 2016;91:585-589.
Karam C, Klein CJ, Dispenzieri A, et al. Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome. Neurology. 2015;84:1981-1987.
Autore F, Innocenti I, Luigetti M, et al. Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome. Hematol Oncol. 2018;36:392-398.
Nozza A, Terenghi F, Gallia F, et al. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017;179:748-755.
Briani C, Manara R, Lessi F, Citton V, Zambello R, Adami F. Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy. Am J Hematol. 2012;87:539-541.
Khan M, Stone K, van Rhee F. Daratumumab for POEMS Syndrome. Mayo Clin Proc. 2018;93:542-544.
Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745-2760.
Visentin A, Facco M, Frezzato F, et al. Integrated CLL scoring system, a new and simple index to predict time to treatment and overall survival in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2015;15:612-620 e611-615.
Raponi S, Del Giudice I, Marinelli M, et al. Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. Ann Oncol. 2018;29:966-972.
Mauro FR, Caputo MD, Rosati S, et al. Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2018;11:601-611.
Autore F, Piccirillo N, Nozza A, et al. Peripheral blood Hemopoietic stem cell mobilization regimens in POEMS syndrome: a retrospective study at 2 hematologic Italian centers. Biol Blood Marrow Transplant. 2019;25:2514-2516.
Zhao H, Huang XF, Gao XM, et al. What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone? Leukemia. 2019;33:1023-1029.
Kuwabara S, Misawa S, Kanai K, et al. Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology. 2008;71:1691-1695.
Zeng K, Yang JR, Li J, et al. Effective induction therapy with subcutaneous administration of bortezomib for newly diagnosed POEMS syndrome: a case report and a review of the literature. Acta Haematol. 2013;129:101-105.
Riva M, Lessi F, Berno T, et al. Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients. Leuk Lymphoma. 2019;60:2067-2070.
Visentin A, Facco M, Gurrieri C, et al. Prognostic and predictive effect of IGHV mutational status and load in chronic lymphocytic leukemia: focus on FCR and BR treatments. Clin Lymphoma Myeloma Leuk. 2019;19:678-685 e674.
Visentin A, Bonaldi L, Rigolin GM, et al. The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. Br J Cancer. 2019;121:150-156.
Briani C, Visentin A, Cavallaro T, et al. Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia. Ann Hematol. 2017;96:159-161.
Visentin A, Briani C, Imbergamo S, et al. Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia. Hematol Oncol. 2018;36:366-369.
Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve society - first revision. Eur J Neurol. 2010;17:356-363.
Visentin A, Deodato M, Mauro FR, et al. A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematol Oncol. 2019;37:508-512.
Briani C, Visentin A, Salvalaggio A, Cacciavillani M, Trentin L. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy. Eur J Neurol. 2019;26:371-375.
Wrotnowski U, Mills SE, Cooper PH. Malignant angioendotheliomatosis. An angiotropic lymphoma? Am J Clin Pathol. 1985;83:244-248.
Ponzoni M, Campo E, Nakamura S. Intravascular large B-cell lymphoma: a chamaleon with multiple faces and many masks. Blood. 2018;132:1561-1567. https://doi.org/10.1182/blood-2017-04-737445. [Epub ahead of print.
Schrader AMR, Jansen PM, Willemze R, et al. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. Blood. 2018;131:2086-2089.
Glass J, Hochberg FH, Miller DC. Intravascular lymphomatosis. A systemic disease with neurologic manifestations. Cancer. 1993;71:3156-3164.
Hundsberger T, Cogliatti S, Kleger GR, et al. Intravascular lymphoma mimicking cerebral stroke: report of two cases. Case Rep Neurol. 2011;3:278-283.
Grisold W, Grisold A, Marosi C, Meng S, Briani C. Neuropathies associated with lymphoma(dagger). Neurooncol Pract. 2015;2:167-178.
Ponzoni M, Ferreri AJ. Intravascular lymphoma: a neoplasm of ‘homeless’ lymphocytes? Hematol Oncol. 2006;24:105-112.
Jiang QL, Pytel P, Rowin J. Disseminated intravascular large-cell lymphoma with initial presentation mimicking Guillain-Barre syndrome. Muscle Nerve. 2010;42:133-136.
Lynch KM, Katz JD, Weinberg DH, Lin DI, Folkerth RD. Isolated mononeuropathy multiplex-a rare manifestation of intravascular large B-cell lymphoma. J Clin Neuromuscul Dis. 2012;14:17-20.
Fukami Y, Koike H, Iijima M, et al. Demyelinating neuropathy due to intravascular large B-cell lymphoma. Intern Med. 2020;59:435-438.
Shimada K, Yamaguchi M, Atsuta Y, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:593-602.
Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7:1018-1029.
Lhermitte J, Trelles J. Neurolymphomatose périphérique humaine. Presse Med. 1934;42:289-292.
Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH. Neurolymphomatosis. Neuro Oncol. 2003;5:104-115.
Campagnolo M, Cacciavillani M, Cavallaro T, et al. Neurolymphomatosis, a rare manifestation of peripheral nerve involvement in lymphomas: suggestive features and diagnostic challenges. J Peripher Nerv Syst. 2020. https://doi.org/10.1111/jns.12401. [published online ahead of print].
Grisariu S, Avni B, Batchelor TT, et al. Neurolymphomatosis: an international primary CNS lymphoma collaborative group report. Blood. 2010;115:5005-5011.
Odabasi Z, Parrott JH, Reddy VV, Oh SJ. Neurolymphomatosis associated with muscle and cerebral involvement caused by natural killer cell lymphoma: a case report and review of literature. J Peripher Nerv Syst. 2001;6:197-203.
Tomita M, Koike H, Kawagashira Y, et al. Clinicopathological features of neuropathy associated with lymphoma. Brain. 2013;136:2563-2578.
Gordon PH, Younger DS. Neurolymphomatosis. Neurology. 1996;46:1191-1192.
van den Bent MJ, de Bruin HG, Beun GD, Vecht CJ. Neurolymphomatosis of the median nerve. Neurology. 1995;45:1403-1405.
Moore KR, Blumenthal DT, Smith AG, Ward JH. Neurolymphomatosis of the lumbar plexus: high-resolution MR neurography findings. Neurology. 2001;57:740-742.
Baehring JM, Batchelor TT. Diagnosis and management of neurolymphomatosis. Cancer J. 2012;18:463-468.
Briani C, Zambello R, Cavallaro T, et al. Improvement of peripheral nervous system manifestations of B-cell non-Hodgkin's lymphoma after rituximab therapy. J Peripher Nerv Syst. 2009;14:146-148.
Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international Extranodal lymphoma study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217-e227.
Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016;3:e163-e175.
Naddaf E, Dispenzieri A, Mandrekar J, Mauermann ML. Clinical spectrum of Castleman disease-associated neuropathy. Neurology. 2016;87:2457-2462.
Chang KC, Wang YC, Hung LY, et al. Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease. Mod Pathol. 2014;27:823-831.
Li Z, Lan X, Li C, et al. Recurrent PDGFRB mutations in unicentric Castleman disease. Leukemia. 2019;33:1035-1038.
Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135:1353-1364.
van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. Hematol Oncol Clin North Am. 2018;32:89-106.
van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15:966-974.
Mishimoto N, Honda O, Sumikawa H, Jokhoh T, Aozasa K, Kanakura Y. Japanese MRA study group on MCD (2007). A long-term (5-year) sustained efficacy of tocilizumab for multicentric Castleman's disease and the effect on pulmonary complications. ASH 2007 congress abstract. Blood. 2007;110(11):646.